\-\ Texto\\:\\ \ \(0\)\
\-\ multiple\\ sub\\-centimeter\\ enhancing\\ nodular\\ lesions\\ of\\ the\\ thoracic\\ spinal\\ cord\\ and\\ conus\\ medullaris\\.\\ \\ lesions\\ are\\ isointense\\ on\\ t2wi\\.\ \(0\)\
\-\ spinal\\ metastases\ \(1\)\
\-\ cerebral\\ glioblastoma\\,\\ ependymoma\\,\\ anaplastic\\ astrocytoma\\,\\ and\\ posterior\\ fossa\\ medulloblastoma\\ are\\ the\\ most\\ common\\ cns\\ primary\\ tumors\\ that\\ metastasize\\ to\\ the\\ spinal\\ subarachnoid\\ space\\.\\ \\ non\\-cns\\ tumors\\ that\\ commonly\\ seed\\ the\\ subarachnoid\\ space\\ include\\ carcinoma\\ of\\ the\\ lung\\ or\\ breast\\,\\ melanoma\\,\\ lymphoma\\,\\ and\\ leukemia\\.\ \(0\)\
\-\ 63\\ yo\\ asymptomatic\\ man\\ presents\\ for\\ annual\\ spine\\ screening\\.\\ \\ patient\\ reports\\ a\\ history\\ of\\ a\\ spinal\\ cord\\ tumor\\ removed\\ \\‚\\Ä\\ú4\\ or\\ 5\\ years\\ ago\\,\\‚\\Ä\\ù\\ though\\ he\\ doesn\\‚\\Ä\\ôt\\ recall\\ the\\ type\\ of\\ tumor\\ and\\ was\\ treated\\ only\\ with\\ surgery\\.\ \(0\)\
\-\ these\\ findings\\ are\\ most\\ likely\\ secondary\\ to\\ the\\ original\\,\\ unknown\\ tumor\\.\\ \\ given\\ the\\ focal\\ nature\\ of\\ the\\ original\\ tumor\\,\\ along\\ with\\ the\\ patient\\'s\\ prolonged\\ course\\ \\(a\\ 2002\\ spinal\\ mri\\ was\\ negative\\ for\\ mets\\)\\ and\\ radiographic\\ findings\\,\\ ependymoma\\ is\\ considered\\ most\\ likely\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ spinal\\:\\ 0\\.358939498674733\ \(0\)\
\-\ original\\:\\ 0\\.2146105686768442\ \(0\)\
\-\ tumor\\:\\ 0\\.211525285418012\ \(0\)\
\-\ the\\:\\ 0\\.2017317267701487\ \(0\)\
\-\ cns\\:\\ 0\\.18882538962601364\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.1819666449379807\ \(0\)\
\-\ ependymoma\\:\\ 0\\.17079807702838357\ \(0\)\
\-\ most\\:\\ 0\\.157846968764244\ \(0\)\
\-\ cord\\:\\ 0\\.1498832632012182\ \(0\)\
\-\ tumors\\:\\ 0\\.14870812847724663\ \(0\)\
\-\ seed\\:\\ 0\\.1422103220081582\ \(0\)\
\-\ space\\:\\ 0\\.1345935432432325\ \(0\)\
\-\ recall\\:\\ 0\\.12850682593018112\ \(0\)\
\-\ metastasize\\:\\ 0\\.1237522959704559\ \(0\)\
\-\ doesn\\:\\ 0\\.1217810078332225\ \(0\)\
\-\ likely\\:\\ 0\\.12083007754779049\ \(0\)\
\-\ medullaris\\:\\ 0\\.1191827067377489\ \(0\)\
\-\ lesions\\:\\ 0\\.11612609535427042\ \(0\)\
\-\ are\\:\\ 0\\.11508889460366269\ \(0\)\
\-\ anaplastic\\:\\ 0\\.11095366730405427\ \(0\)\
\-\ conus\\:\\ 0\\.10858704696542355\ \(0\)\
\-\ t2wi\\:\\ 0\\.10814941175454379\ \(0\)\
\-\ medulloblastoma\\:\\ 0\\.10499026032595547\ \(0\)\
\-\ and\\:\\ 0\\.10445569350765654\ \(0\)\
\-\ mets\\:\\ 0\\.10393707970143636\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.1008197121637614\ \(0\)\
\-\ findings\\:\\ 0\\.09979410389242122\ \(0\)\
\-\ of\\:\\ 0\\.09892440359824756\ \(0\)\
\-\ prolonged\\:\\ 0\\.09792504902886133\ \(0\)\
\-\ 63\\:\\ 0\\.09768391162856416\ \(0\)\
\-\ 2002\\:\\ 0\\.09675088960341101\ \(0\)\
\-\ melanoma\\:\\ 0\\.09441269481300682\ \(0\)\
\-\ annual\\:\\ 0\\.0934439659751888\ \(0\)\
\-\ leukemia\\:\\ 0\\.0923473280534083\ \(0\)\
\-\ isointense\\:\\ 0\\.09148260409165652\ \(0\)\
\-\ nature\\:\\ 0\\.08926429696596948\ \(0\)\
\-\ though\\:\\ 0\\.08783422112602436\ \(0\)\
\-\ that\\:\\ 0\\.08774747534905243\ \(0\)\
\-\ removed\\:\\ 0\\.08588463945264334\ \(0\)\
\-\ screening\\:\\ 0\\.08212782169863445\ \(0\)\
\-\ metastases\\:\\ 0\\.08173395381132231\ \(0\)\
\-\ nodular\\:\\ 0\\.08051117069139574\ \(0\)\
\-\ fossa\\:\\ 0\\.0793673334726916\ \(0\)\
\-\ considered\\:\\ 0\\.07878069231203447\ \(0\)\
\-\ reports\\:\\ 0\\.07861658627364736\ \(0\)\
\-\ unknown\\:\\ 0\\.07661094227293963\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.07632157542847531\ \(0\)\
\-\ thoracic\\:\\ 0\\.07554934801165199\ \(0\)\
\-\ radiographic\\:\\ 0\\.07500813571436371\ \(0\)\
\-\ commonly\\:\\ 0\\.07480936736348791\ \(0\)\
\-\ course\\:\\ 0\\.07467808287044965\ \(0\)\
\-\ ago\\:\\ 0\\.07397290276279106\ \(0\)\
\-\ breast\\:\\ 0\\.07341610329034495\ \(0\)\
\-\ was\\:\\ 0\\.07046890920203826\ \(0\)\
\-\ or\\:\\ 0\\.07034198650452006\ \(0\)\
\-\ cerebral\\:\\ 0\\.07004321428025939\ \(0\)\
\-\ given\\:\\ 0\\.06954673012039123\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.06882714581300645\ \(0\)\
\-\ type\\:\\ 0\\.06782194561633835\ \(0\)\
\-\ along\\:\\ 0\\.06773332880411942\ \(0\)\
\-\ spine\\:\\ 0\\.0667867126647657\ \(0\)\
\-\ patient\\:\\ 0\\.06576570282107277\ \(0\)\
\-\ enhancing\\:\\ 0\\.06333330343240459\ \(0\)\
\-\ yo\\:\\ 0\\.06316173069348223\ \(0\)\
\-\ only\\:\\ 0\\.06316173069348223\ \(0\)\
\-\ treated\\:\\ 0\\.0629580120652689\ \(0\)\
\-\ negative\\:\\ 0\\.06259050298657161\ \(0\)\
\-\ primary\\:\\ 0\\.06216577624350213\ \(0\)\
\-\ years\\:\\ 0\\.061973129504151174\ \(0\)\
\-\ lung\\:\\ 0\\.06150047948006476\ \(0\)\
\-\ for\\:\\ 0\\.061285448489037074\ \(0\)\
\-\ carcinoma\\:\\ 0\\.06047362833310332\ \(0\)\
\-\ focal\\:\\ 0\\.06047362833310332\ \(0\)\
\-\ lymphoma\\:\\ 0\\.060211487268822715\ \(0\)\
\-\ include\\:\\ 0\\.06015375651575842\ \(0\)\
\-\ secondary\\:\\ 0\\.05992469580852041\ \(0\)\
\-\ he\\:\\ 0\\.0598678902293778\ \(0\)\
\-\ common\\:\\ 0\\.05733544877481206\ \(0\)\
\-\ these\\:\\ 0\\.05709132197394967\ \(0\)\
\-\ surgery\\:\\ 0\\.05435579601815298\ \(0\)\
\-\ man\\:\\ 0\\.05352375274300918\ \(0\)\
\-\ posterior\\:\\ 0\\.05227983582952757\ \(0\)\
\-\ mri\\:\\ 0\\.05189592207082309\ \(0\)\
\-\ to\\:\\ 0\\.05054975154198079\ \(0\)\
\-\ multiple\\:\\ 0\\.049450355830969954\ \(0\)\
\-\ presents\\:\\ 0\\.04863446166205559\ \(0\)\
\-\ with\\:\\ 0\\.03959340436233005\ \(0\)\
\-\ history\\:\\ 0\\.03862616639533299\ \(0\)\
\-\ on\\:\\ 0\\.030534025188552468\ \(0\)\
\-\ is\\:\\ 0\\.02768700333267541\ \(0\)\
